1 |
Al-Moundhri M, Al-Bahrani B, Pervez I, et al (2004).The outcome of treatment of breast cancer in a developing country-oman. The Breast, 13, 139-45.
DOI
ScienceOn
|
2 |
Arends L.R, Myriam Hunink M.G, Stijnen Th (2008).Metaanalysis of summary survival curve data. Statistics in Med, 27, 4381-96.
DOI
ScienceOn
|
3 |
American Cancer Society (2010).Breast cancer facts & figures .Atlanta; American Cancer Society, Inc.
|
4 |
Arkoob K, Al-Nsour M, Al-Nemry O, Al-Hajawi B (2010). Epidemiology of breast cancer in women in Jordan: patient characteristics and survival analysis. East Mediterr Hlth J, 16, 1032-8.
|
5 |
Abbas H, Elyamany A, Salem M, et al (2011). The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med, 4, 35-42.
DOI
ScienceOn
|
6 |
Wang SH, Yanxia S, Yuan ZH, et al (2011). Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Med Oncol, 11, 9964-72.
|
7 |
Yan PW, Huang XE (2010). Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/ cyclophosphamide (FEC). Asian Pac J Cancer Prev, 11, 1115-8.
|
8 |
Zhang J, Yan LIU (2008). HER2 over-expression and response to different chemotherapy regimens in breast cancer. J Zhejinang University Science, 9, 5-9.
DOI
ScienceOn
|
9 |
Brunner, Suddarth's (2008). Textbook of medical-surgical nursing. 11th Edition, chapter 1.
|
10 |
Dear KBG (1994). Iterative generalized least squares for metaanalysis of survival data at multiple times. Biometrics, 50, 989-1002.
DOI
ScienceOn
|
11 |
Duolao W, Ameet B, Felicity C (2006). A Practical Guide to Design, Analysis, and Reporting Clinical Trials. London Remedica, chapter 38.
|
12 |
Dersimonian R, Kacher R (2007). Random-effect model for meta-analysis of clinical trials: an update. Contemp Clinical Trials, 28, 105-14.
DOI
ScienceOn
|
13 |
Di Leo A, Desmedt C, Bartlett J, et al (2011). HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol, 12, 1134-42.
DOI
ScienceOn
|
14 |
Faradmal J, Kazemnejad A, Khoda BR, Hajizade E, Gohari MR (2010). Comparing three adjuvant chemotherapy regimens after modified radical mastectomy in breast cancer patients using log-logistic model. Sci J Semnan Univ Med Sci, 11, 279-86.
|
15 |
Hedges LV, Vevea JL (1998). Fixed and random effects model in meta-analysis. Psychological Methods, 3, 486-504.
DOI
ScienceOn
|
16 |
Ismaili N, Mellas N, Masbah O, et al (2009). Concurrent chemoradiotherapy in adjuvant treatment of breast cancer. Radiat Oncol, 4, 12-25.
DOI
ScienceOn
|
17 |
Ismaili N, Elmajjaoui S, Lalya I, et al (2010). Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution. BMC Res Notes, 3, 247-57.
|
18 |
Katalinic A, Pritzkuleit R, Waldmann A (2009). Recent trends in breast cancer incidence and mortality in Germany. Breast Care, 4, 75-80.
DOI
ScienceOn
|
19 |
Kleinbaum D (2004). Survival analysis a self- learning text. Springer.
|
20 |
Kuru B, Camlibel M, Dine S, et al (2005). A comparison of the outcomes of non-randomized chemotherapy regimens in node positive breast cancer. J Exp Clin Cancer Res, 3, 363-71.
|
21 |
Kim K, Chie EK, Han W, et al (2011).Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. Tumori, 97, 280-5.
|
22 |
Lian-Fang Li, Xiao-Jing Xu, Zhao Y, et al (2008). Integrated gene expression profile predicts prognosis of breast cancer patients. Breast Cancer Res Treat, 113, 231-7.
|
23 |
Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in iran: an epidemiological review. The Breast J, 13, 383-91.
DOI
ScienceOn
|
24 |
Sakakibara M, Nagashima T, Kadowaki M, et al (2009). Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases. Ann Surg Oncol, 16, 2470-8.
DOI
|
25 |
Wong ZW, Ang PCS (2008). Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in asian women with metastatic breast cancer. The Breast, 17, 517-22.
DOI
ScienceOn
|